MARKET

OSUR

OSUR

OraSure Tech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.91
-0.27
-2.42%
Closed 19:31 09/24 EDT
OPEN
11.17
PREV CLOSE
11.18
HIGH
11.21
LOW
10.73
VOLUME
594.85K
TURNOVER
--
52 WEEK HIGH
17.79
52 WEEK LOW
8.58
MARKET CAP
785.62M
P/E (TTM)
149.17
1D
5D
1M
3M
1Y
5Y
FDA Establishes Additional Conditions Of Emergency Use Nod For COVID-19 Tests For Viral Mutations
The FDA has issued a letter to establish additional conditions of Emergency Use Authorizations (EUAs) manufacturers of COVID-19 tests.
Benzinga · 2d ago
OraSure Secures $13.6M BARDA Funding For InteliSwab COVID-19 Test 510(k) Clearance and CLIA Waiver
Benzinga · 3d ago
BRIEF-OraSure To Receive Up To $13.6 Mln To Support COVID-19 Test 510(K) Clearance
reuters.com · 3d ago
OraSure Technologies Reports Will Receive U p To $13.6M From Biomedical Advanced Research Development Authority To Support InteliSwab COVID-19 Rapid Test 510(k) Clearance, Clinical Lab Improvement Amendments Waiver
OraSure Technologies, Inc. (NASDAQ:OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Biomedical Advanced Research Development Authority
Benzinga · 3d ago
OraSure to Receive up to $13.6 Million from Biomedical Advanced Research Development Authority to Support InteliSwab(TM) COVID-19 Rapid Test 510(k) Clearance and CLIA Waiver
OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Biomedical Advanced Research Development Authority (BARDA), part of the office of the Assis...
GlobeNewswire · 3d ago
OraSure Technologies to Receive Up to $13.6 Million From BARDA for Its COVID-19 Rapid Test
MT Newswires · 3d ago
U.S. to buy $554 million worth of rapid COVID-19 antigen tests from Abbott
The U.S. government is set to spend $554.4 million to buy rapid COVID-19 tests from Abbott Laboratories (NYSE:ABT) in a bid to supply nursing homes and other high-risk populations, Reuters reported citing
Seekingalpha · 4d ago
Raymond James Downgrades OraSure Technologies to Market Perform
Raymond James analyst Andrew Cooper downgrades OraSure Technologies (NASDAQ:OSUR) from Outperform to Market Perform.
Benzinga · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OSUR. Analyze the recent business situations of OraSure Tech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OSUR stock price target is 14.40 with a high estimate of 20.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 292
Institutional Holdings: 72.09M
% Owned: 100.12%
Shares Outstanding: 72.01M
TypeInstitutionsShares
Increased
56
5.08M
New
27
502.95K
Decreased
67
3.84M
Sold Out
31
1.38M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.61%
Healthcare Equipment & Supplies
-0.42%
Key Executives
Non-Executive Chairman/Independent Director
Michael Celano
President/Chief Executive Officer/Director
Stephen Tang
Chief Financial Officer/Senior Vice President/Director of Investor Relations
Scott Gleason
Executive Vice President
Lisa Nibauer
Executive Vice President
Kathleen Weber
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Jack Jerrett
Vice President - Finance/Controller
Michele Miller
Independent Director
Mara Aspinall
Independent Director
James Datin
Independent Director
Eamonn Hobbs
Independent Director
Ronny Lancaster
Independent Director
Lelio Marmora
Independent Director
David Shulkin
No Data
About OSUR
OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing.

Webull offers kinds of OraSure Technologies, Inc. stock information, including NASDAQ:OSUR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OSUR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OSUR stock methods without spending real money on the virtual paper trading platform.